Off patent medicines account for 70% of those dispensed in Europe for the most prominent diseases such as cancer, diabetes, cardiovascular care, infectious diseases, and others. Between 70-90% of Intensive Care Unit (ICU), and emergency medicines are off patent. Our sector currently has over 400 manufacturing sites in Europe. Therefore, the off patent medicines industry sector must be included in the 'Important Project of Common European Interest' (IPCEI) on Health.
Please find here the press release of our European association, Medicines for Europe.
Dutch: Edito 'Business as usual?', Europese off-patent sector zeer bezorgd over negatieve impact van torenhoge inflatie op beschikbaarheid van geneesmiddelen, Biosimilars in het medicomut-akkoord, #NoFilter Interview K. Straetmans (APB) & J. Van Assche (Medaxes) - Deel 2
French: Edito 'Business as usual?', Le secteur européen des médicaments hors brevet très préoccupé par l'impact négatif de l'inflation galopante sur la disponibilité des médicaments, Médicaments biosimilaires dans l'accord médicomut, #NoFilter: interview du pharmacien Koen Straetmans (APB) et de Joris Van Assche (Medaxes) -
Missed out on the Generic medicines day webinar of 28 October 2021?
Scroll down the homepage of our website to replay.
With the support of the Belgian and Luxembourg Competent Authorities, in 2018 the pharmaceutical industry launched the 'e-PIL' pilot project in Belgian and Luxembourg hospitals. The project is the result of a derogation obtained from the European Commission.
Replay of the Generic Medicines Day webinar (in Dutch and French)
With the support of the Belgian and Luxembourg Competent Authorities, in 2018 the pharmaceutical industry launched the 'e-PIL' pilot project in Belgian and Luxembourg hospitals. The project is the result of a derogation obtained from the European Commission. In this pilot project, a selection of medicines on the Belgian and Luxembourg market are not accompanied by their patient paper inserted leaflet (PIL).
For the treatment of the Corona virus, Medaxes refers to the scientific guidelines issued by the scientific institutions of our country.
These informations are regularly updated, taking into account the latest scientific findings. For more information, please click on Sciensano Epidemio
A new report by KPMG titled ‘Improving healthcare delivery in hospitals by optimized utilization of medicines’ (08/10/2019) analyses the financing and procurement of medicines in hospitals in 8 European countries.
Medicines for Europe and Medaxes urge the EU institutions to adopt the SPC manufacturing waiver for patients, sustainable healthcare and manufacturing jobs
Video on the origins and application of this European Directive to combat the entry of falsified medicines into the legal supply chain. Also the Medaxes members fully support this Directive.
FeBelGen, the association representing generic medicines companies since 2001, makes way for Medaxes, a broader umbrella organisation covering all medicines and self-care products that contribute to the accessibility of healthcare. In addition to generic and biosimilar medicines, Medaxes sees an increasingly prominent role ahead for properly framed self-care, through self-care medicines, self-care medical devices and food supplements freely available from pharmacies.